Handelsbanken Fonder AB Decreases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Handelsbanken Fonder AB lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 42.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 48,154 shares of the biopharmaceutical company's stock after selling 35,486 shares during the quarter. Handelsbanken Fonder AB's holdings in Regeneron Pharmaceuticals were worth $34,302,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. State Street Corp boosted its stake in shares of Regeneron Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company's stock valued at $5,153,603,000 after buying an additional 61,277 shares in the last quarter. International Assets Investment Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company's stock worth $926,078,000 after purchasing an additional 879,916 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company's stock valued at $707,759,000 after purchasing an additional 11,499 shares in the last quarter. Swiss National Bank lifted its stake in shares of Regeneron Pharmaceuticals by 0.6% in the third quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company's stock valued at $338,079,000 after purchasing an additional 2,000 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. boosted its holdings in Regeneron Pharmaceuticals by 0.4% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 302,616 shares of the biopharmaceutical company's stock worth $215,562,000 after buying an additional 1,108 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Up 0.6 %

Regeneron Pharmaceuticals stock traded up $4.31 during midday trading on Friday, reaching $700.33. The stock had a trading volume of 727,332 shares, compared to its average volume of 923,518. The stock's 50-day simple moving average is $700.02 and its 200 day simple moving average is $886.33. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The stock has a market capitalization of $76.56 billion, a PE ratio of 18.29, a price-to-earnings-growth ratio of 2.30 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period in the previous year, the company posted $11.86 EPS. The company's revenue was up 10.3% compared to the same quarter last year. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.50%.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Morgan Stanley dropped their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating for the company in a report on Friday, November 1st. Leerink Partners raised Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and raised their price objective for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th. Royal Bank of Canada decreased their target price on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an "outperform" rating on the stock in a research report on Friday, November 1st. BMO Capital Markets dropped their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating for the company in a research report on Tuesday, February 4th. Finally, Evercore ISI decreased their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating on the stock in a research report on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.